Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, the company expects net product revenue of between $2.8 and $2.9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 USD | +1.68% | -1.63% | -88.87% |
07-01 | Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index | CI |
07-01 | Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Growth Index | CI |
1st Jan change | Capi. | |
---|---|---|
-88.87% | 66.47M | |
+54.07% | 809B | |
+38.95% | 621B | |
-7.05% | 351B | |
+15.44% | 319B | |
+5.72% | 289B | |
+14.21% | 238B | |
-0.45% | 221B | |
+14.58% | 218B | |
+7.42% | 166B |